Richard Wooster
Overview
Explore the profile of Richard Wooster including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
13320
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kim N, He N, Kim C, Zhang F, Lu Y, Yu Q, et al.
Int J Cancer
. 2012 Mar;
131(10):2456-64.
PMID: 22422301
A systematic understanding of genotype-specific sensitivity or resistance to anticancer agents is required to provide improved patient therapy. The availability of an expansive panel of annotated cancer cell lines enables...
12.
Liu-Sullivan N, Zhang J, Bakleh A, Marchica J, Li J, Siolas D, et al.
Oncotarget
. 2012 Jan;
2(12):1254-64.
PMID: 22248814
RNAi screening holds the promise of systemizing the search for combination therapeutic strategies. Here we performed a pooled shRNA library screen to look for promising targets to inhibit in combination...
13.
Jing J, Greshock J, Holbrook J, Gilmartin A, Zhang X, McNeil E, et al.
Mol Cancer Ther
. 2011 Dec;
11(3):720-9.
PMID: 22169769
The MEK1 and MEK2 inhibitor GSK1120212 is currently in phase II/III clinical development. To identify predictive biomarkers, sensitivity to GSK1120212 was profiled for 218 solid tumor cell lines and 81...
14.
Moy C, Oleykowski C, Plant R, Greshock J, Jing J, Bachman K, et al.
J Transl Med
. 2011 Jul;
9:110.
PMID: 21762492
Background: Aurora kinases play critical roles in mitosis and are being evaluated as therapeutic targets in cancer. GSK1070916 is a potent, selective, ATP competitive inhibitor of Aurora kinase B and...
15.
Moy C, Aziz M, Greshock J, Szabo S, McNeil E, Jing J, et al.
Genomics
. 2011 May;
98(4):296-301.
PMID: 21600279
Identification of biomarkers for positive and negative predictors of response to cancer therapeutics can help direct clinical strategies. However, challenges with tissue availability and costs are significant limiting factors for...
16.
Pietrak B, Zhao H, Qi H, Quinn C, Gao E, Boyer J, et al.
Biochemistry
. 2011 Apr;
50(21):4804-12.
PMID: 21524095
Heterozygously expressed single-point mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2, respectively) render these dimeric enzymes capable of producing the novel metabolite α-hydroxyglutarate (αHG). Accumulation of αHG is...
17.
Degenhardt Y, Greshock J, Laquerre S, Gilmartin A, Jing J, Richter M, et al.
Mol Cancer Ther
. 2010 Jun;
9(7):2079-89.
PMID: 20571075
Polo-like kinases are a family of serine threonine kinases that are critical regulators of cell cycle progression and DNA damage response. Predictive biomarkers for the Plk1-selective inhibitor GSK461364A were identified...
18.
Greshock J, Bachman K, Degenhardt Y, Jing J, Wen Y, Eastman S, et al.
Cancer Res
. 2010 Apr;
70(9):3677-86.
PMID: 20406975
Preclinical cellular response profiling of tumor models has become a cornerstone in the development of novel cancer therapeutics. As efforts to predict clinical efficacy using cohorts of in vitro tumor...
19.
Wooster R, Bachman K
Curr Opin Genet Dev
. 2010 Apr;
20(3):336-41.
PMID: 20382522
DNA sequence and bioinformatics technology have enabled the analysis of the cancer genome, revealing the vast genetic complexity of this disease. The patterns of somatic mutations are a rich archaeological...
20.
Balamuth N, Wood A, Wang Q, Jagannathan J, Mayes P, Zhang Z, et al.
Cancer Res
. 2010 Mar;
70(7):2749-58.
PMID: 20233875
Cancer genomic studies that rely on analysis of biopsies from primary tumors may not fully identify the molecular events associated with tumor progression. We hypothesized that characterizing the transcriptome during...